ertugliflozin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sodium glucose co-transporter inhibitors, phlorizin derivatives 5270 1210344-57-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ertugliflozin
  • PF-04971729-00
  • steglatro
  • ertugliflozin L-pyroglutamic acid
  • PF-04971729
SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
  • Molecular weight: 436.89
  • Formula: C22H25ClO7
  • CLOGP: 3.19
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 4
  • TPSA: 108.61
  • ALOGS: -3.57
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 21, 2018 EMA Merck Sharp & Dohme Limited
Dec. 19, 2017 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD23 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD24 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BK04 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D000077203 Sodium-Glucose Transporter 2 Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.68 acidic
pKa2 12.61 acidic
pKa3 13.22 acidic
pKa4 13.51 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
15MG STEGLATRO MERCK SHARP DOHME N209803 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
5MG STEGLATRO MERCK SHARP DOHME N209803 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
15MG;EQ 100MG BASE STEGLUJAN MERCK SHARP DOHME N209805 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
5MG;EQ 100MG BASE STEGLUJAN MERCK SHARP DOHME N209805 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
2.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
2.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
7.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
7.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium/glucose cotransporter 2 Transporter INHIBITOR IC50 9.06 SCIENTIFIC LITERATURE DRUG LABEL
Sodium/glucose cotransporter 1 Transporter INHIBITOR IC50 5.71 SCIENTIFIC LITERATURE
Low affinity sodium-glucose cotransporter Transporter IC50 9.06 CHEMBL
Sodium/glucose cotransporter 2 Transporter IC50 8.94 CHEMBL

External reference:

IDSource
4037222 VANDF
C4079805 UMLSCUI
CHEMBL1770248 ChEMBL_ID
DB11827 DRUGBANK_ID
D10313 KEGG_DRUG
C570288 MESH_SUPPLEMENTAL_RECORD_UI
44814423 PUBCHEM_CID
8376 IUPHAR_LIGAND_ID
9460 INN_ID
6C282481IP UNII
1992672 RXNORM
267231 MMSL
d08689 MMSL
017435 NDDF
764274008 SNOMEDCT_US
764275009 SNOMEDCT_US

Pharmaceutical products:

None